Chronic myelogenous leukemia interferon alfa

Guilhot, F. et al., Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group, N. Engl. [Pg.166]

F. Role in therapy According to Micromedex, Roferon-A is recommended as the drug of choice in renal carcinoma and the chronic phase of chronic myelogenous leukemia. The role of Gleevec (Ima-tinib) in CML is yet to be determined, but it may replace the use of interferon alfa-2a. Roferon-A is an alternative (for unrespon-sive/intolerant patients) to current regimens of choice in hairy-cell leukemia, multiple myeloma, metastatic melanoma, and AIDS-related Kaposi s sarcoma. Other alpha interferons appear to have similar efficacy and can be used in lieu of Roferon-A in some instances. In particular, interferon alfa-2b (Intron) can be considered to have the same role as interferon alfa-2a in chronic hepatitis C, Kaposi s sarcoma, and hairy-cell leukemia. [Pg.191]

H. Other considerations Interferon alfa-2a has been designated an orphan drug product for the treatment of chronic myelogenous leukemia, AIDS-related Kaposi s sarcoma, renal cell carcinoma, metastatic malignant melanoma, and esophageal and colorectal cancer. [Pg.192]

Roferon-A Interferon alfa-2a Hoffman- LaRoche 6/1986 Hairy cell leukemia/ AIDS-related Kaposi s sarcoma/hepatitis C/chronic myelogenous leukemia E. coli... [Pg.1426]

Hensley ML, Peterson B, Silver RT, Larson RA, Schiffer CA, Szatrowski TP. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia analysis of Cancer and Leukemia Group B 9013. J Clin Oncol 2000 18(6) 1301-8. [Pg.710]

Interferon alfa-2a Roferon-A (Roche) Hairy cell leukemia AIDS-related Kaposi s sarcoma Chronic myelogenous leukemia... [Pg.271]

Rapid exacerbation (1-21 days) or delayed (3-38 months) de novo appearance of immune hemolytic anemia has been reported after initiation of interferon alfa treatment in nine patients with lymphoproliferative disorders (220). However, this rare event was identified in only 1% of 581 patients receiving interferon alfa alone or as part of a chemotherapeutic regimen for chronic myelogenous leukemia (221). A mechanism close to that observed with alpha-methyldopa has been thought to be involved (208). The direct antiglobulin test was positive in 32% of 28 chronic myeloid leukemia patients after a median of 1 year of treatment with interferon alfa (222). [Pg.1806]

Thrombotic thrombocytopenic purpura is a possible complication of interferon alfa in patients with chronic myelogenous leukemia, and can develop even after a successful prolonged (2-3 years) treatment (234). Complete recovery is expected after prompt medical management with plasma exchange and glucocorticoids. [Pg.1806]

There was significant bleeding with hematomas in association with an inhibitor of factor VIII in a 58-year-old man who took interferon alfa for 1 year for chronic myelogenous leukemia (239). The factor VIII inhibitor, which was markedly raised, disappeared within 6 weeks of interferon alfa withdrawal and prednisone treatment. [Pg.1807]

Three patients developed unilateral or bilateral avascular necrosis of the femoral head after 3-54 months of treatment with interferon alfa for chronic myelogenous leukemia (314). One required bilateral hip replacement and two significantly improved after interferon alfa withdrawal. One patient received further interferon alfa without exacerbation. [Pg.1812]

Characteristic features of Behget s disease or isolated positive skin tests were found in one study of patients with chronic myelogenous leukemia treated with interferon alfa (346). No other reports confirmed these findings. [Pg.1814]

There is a debate as to whether previous interferon alfa adversely affects the outcome of bone marrow transplantation in chronic myelogenous leukemia. [Pg.1816]

In a retrospective study of 153 patients who underwent bone-marrow transplantation for chronic myelogenous leukemia, pretransplant interferon alfa treatment for more than 12 months was associated with a significant increase in transplant-related mortality during the first 2 years when compared with patients who received pretransplant interferon alfa for less than 12 months (28 of 46 patients versus nine of 38) (384). This adverse outcome was also more frequent in patients who discontinued treatment less than 3 months before transplantation. [Pg.1816]

Sacchi S, Kantarjian H, O Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia. J Chn Oncol 1995 13(9) 2401-7. [Pg.1825]

English KE, Brien WF, Howson-Jan K, Kovacs MJ. Acquired factor VIII inhibitor in a patient with chronic myelogenous leukemia receiving interferon-alfa therapy. Ann Pharmacother 2000 34(6) 737-9. [Pg.1825]

Interferon alfa-2a is an immunomodulator. Interferon alfa-2a has antiproliferative and immunomodulatory activities. Its elimination half-life is 3.7 to 8.5 hr after IV infusion. Adult use for hairy cell leukemia, AIDS-related Kaposi s sarcoma, chronic myelogenous leukemia pediatric use for chroiuc myelogenous leukemia. [Pg.355]

Biological response modifiers Antibodies Interferon-alfa, interleukin 2 Hairy cell leukemia Kaposi s sarcoma melanoma carcinoid renal ceU ovary bladder non-Hodgkin s lymphoma mycosis fungoides multiple myeloma chronic myelogenous leukemia malignant melanoma... [Pg.856]

Ohnishi K, Ohno R, Tomonaga M et al (1995) A randomized trial comparing interferon-alfa with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 86 906-916... [Pg.144]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...